This past August Nanoligent was featured in the Spanish economy newspaper elEconomista. After a brief review on the importance of technology improvements for cancer treatment, Nanoligent technology is highlighted for its selectivity, efficiency, and low toxicity.
As it is explained in the article, Nanoligent drug acts only on cancer cells, based on the specific interaction between a protein present in the nanoparticle and a cell receptor (CXCR4), which is overexpressed in tumor cells. Currently, there are no drugs on the market that selectively eliminate metastatic stem cells so researchers consider Nanoligent’s technology has a lot of potential and could have a high clinical impact as regulatory trials are passed.
